I can understand where the frustration is coming from, especially for those who bought high and wanting to sell low. But take away the SP action in the last 6 months, and focus on the company's progress, a lot has happened and there's also a lot more to come.
AngelMed implant in Australia - anticipated in Q2 FY20-21 - which there could be a slight delay
AngelMed FDA approval for 2nd gen battery Q3 FY20-21
AngelMed can generate over $35m p.a. based on 1% uptake.
Phyrari FFR-Wire human trials starts Q3 FY20-21
Phyrari FFR-Wire is a $80m+ p.a. market opportunity
Anticipate cash operating breakeven (or not profitable) for FY20-21. Our revenue was growing steadily before Covid hit.
$9.5m pro forma cash on hand
All of the above plus a pipeline of $50m+ of projects anticipated for 2nd half of FY20-21, which I think leaves us in a strong position for growth in the coming months/year. Again, I know the SP has not reflected on the company's progress, but I think it's just a matter of time until the numbers show up in the quarterlies and heads will start to turn.
Comparing now to a couple of years ago when the SP was $1+ (after consolidation), HYD is in a much better position fundamentally, for a $40m company, I think it is worth the punt and patience will be rewarded.
HYD Price at posting:
25.0¢ Sentiment: Buy Disclosure: Held
